{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"TSC2, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in a diverse range of cancers. Germline and somatic TSC2 mutations are a feature of the disease Tuberous sclerosis complex (TSC).",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"08/18/2019",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "22903760"
      ]
    },
    "description":"The TSC2 R245H mutation is located in the N-terminal domain of the protein. Expression of this mutation in HEK293 cells demonstrated it is likely neutral as measured by TSC1 signal, TSC2 signal, T389/S6K ratio and computational modeling by SIFT comparable to wildtype TSC2 (PMID: 22903760).",
    "knownEffect":"Likely Neutral"
  },
  "oncogenic":"Likely Neutral",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"R245H",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":7249,
    "hgvs":"16:g.2056729G>A",
    "hugoSymbol":"TSC2",
    "id":null,
    "proteinEnd":245,
    "proteinStart":245,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The TSC2 R245H mutation is likely neutral.",
  "vus":false
}